Cargando…
Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression
BACKGROUND: It is currently unknown whether early B cell reconstitution (EBR) in MS patients under rituximab is associated with a risk of relapse or progression. OBJECTIVES: Analyzing EBR in rituximab-treated patients and its putative association with clinical findings. METHODS: Prospective lymphocy...
Autores principales: | Dorcet, Guillaume, Migné, Hugo, Biotti, Damien, Bost, Chloé, Lerebours, Fleur, Ciron, Jonathan, Treiner, Emmanuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159933/ https://www.ncbi.nlm.nih.gov/pubmed/35652942 http://dx.doi.org/10.1007/s00415-022-11197-6 |
Ejemplares similares
-
Glucocorticoid use as a cause of non-cellular immune response to SARS-Cov2 Spike in patients with immune system diseases
por: Renaudineau, Yves, et al.
Publicado: (2022) -
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis
por: Starvaggi Cucuzza, Chiara, et al.
Publicado: (2022) -
Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?
por: Claverie, Roxane, et al.
Publicado: (2023) -
Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review
por: Castillo-Trivino, Tamara, et al.
Publicado: (2013) -
Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
por: Gilmore, Wendy, et al.
Publicado: (2020)